Document is current
Any future updates will be listed below
-
Authors
Freeman, C L
Dixon, M
Houghton, R
Kreuzer, K-A
Fingerle-Rowson, G
Herling, M
Humphrey, K
Böttcher, S
de Costa, C S
Iglesias, V
Stilgenbauer, S
Gribben, J
Hallek, M
Goede, V
- License Information
-
More Information
Article History
First Online: 4 March 2016
Competing interests
: CLF has received research funding, honoraria and other remuneration (travel, accommodation and expenses) from F. Hoffmann-La Roche Ltd. MD, RH, GF-R, KH, CSdC and VI are employees of F. Hoffmann-La Roche Ltd; MD and GF-R have stock ownership in F. Hoffmann-La Roche Ltd, which is publicly traded. K-AK has received consultancy fees, research funding, honoraria and paid expert testimony from F. Hoffmann-La Roche Ltd. SB has received consultancy fees and other remuneration (travel, accommodation and expenses) from AbbVie and F. Hoffmann-La Roche Ltd, research funding from AbbVie, Celgene Corporation and F. Hoffmann-La-Roche Ltd and honoraria from AbbVie, Becton Dickinson and F. Hoffmann-La Roche Ltd. SS has received consultancy fees and research funding from F. Hoffmann-La Roche Ltd/Genentech Inc. JGG has received honoraria from Celgene Corporation, Gilead Sciences, F. Hoffmann-La Roche Ltd, Janssen-Cilag Ltd and Pharmacyclics LLC and other remuneration (travel, accommodation and expenses) from Gilead Sciences. MHa has received consultancy fees and research funding from, and served on a Speaker’s Bureau for, F. Hoffmann-La Roche Ltd. VG has received consultancy fees and research funding from F. Hoffmann-La Roche Ltd, and honoraria from Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, GlaxoSmithKline and Mundipharma. MHe declares no conflicts of interest.
